There is still no cure, but what advances have been made in managing this disabling condition?
In its more aggravated forms diffuse scleroderma is one of the most terrible of all human ills. Like Tithonus [a Greek mythological hero who was granted immortality but not eternal youth] to “wither slowly” and like him to be “beaten down and marred and wasted” until one is literally a mummy, encased in an evershrinking, slowly contracting skin of steel, is a fate not pictured in any tragedy, ancient or modern.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Silverman ME, Murray TJ, Bryan CS, editors. The quotable Osler. Philadelphia: American College of Physicians–American Society of Internal Medicine, 2003: 139.
- 2. Englert H, Small-McMahon J, Davis K, et al. Systemic sclerosis prevalence and mortality in Sydney 1974–88. Aust N Z J Med 1999; 29: 42-50.
- 3. Chandran G, Smith M, Ahern MJ, Roberts-Thomson PJ. A study of scleroderma in South Australia: prevalence, subset characteristics and nailfold capillaroscopy. Aust N Z J Med 1995; 25: 688-694.
- 4. Zochling J, Lewis P, Morley P, et al. Scleroderma: the Tassie experience: P31. Intern Med J 2009; 39 Suppl 2: A62.
- 5. United States Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. Baltimore: Williams and Wilkins, 1996.
- 6. Tyndall A, Black C, Finke J, et al. Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation. Lancet 1997; 349: 254.
- 7. Tyndall A, Furst DE. Adult stem cell treatment of scleroderma. Curr Opin Rheumatol 2007; 19: 604-610.
- 8. Chen FH, Tuan RS. Mesenchymal stem cells in arthritic diseases. Arthritis Res Ther 2008; 10: 223.
- 9. Clements PJ, Furst DE, Wong WK, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999; 42: 1194-1203.
We have both received financial research support from Actelion (manufacturer of bosentan) in the past.